Difference between revisions of "Turner JH, et al. Cancer Biother. Radiopharm. (2003) cited as Ref 550 in DOI: 10.1038/s41392-020-0110-5 (Q9813)"
Jump to navigation
Jump to search
(Created claim: First Author string (P149): Turner JH, #quickstatements; #temporary_batch_1589996169159) |
(Created claim: Fifth Author string (P153): Leahy MF, #quickstatements; #temporary_batch_1590155508986) |
||||||||||||||
| (10 intermediate revisions by the same user not shown) | |||||||||||||||
| Property / Second Author string | |||||||||||||||
| + | Martindale AA | ||||||||||||||
| Property / Second Author string: Martindale AA / rank | |||||||||||||||
| + | Normal rank | ||||||||||||||
| Property / Third Author string | |||||||||||||||
| + | Boucek J | ||||||||||||||
| Property / Third Author string: Boucek J / rank | |||||||||||||||
| + | Normal rank | ||||||||||||||
| Property / DOI Identifier | |||||||||||||||
| + | |||||||||||||||
| Property / DOI Identifier: 10.1089/108497803322287583 / rank | |||||||||||||||
| + | Normal rank | ||||||||||||||
| Property / PubMed ID | |||||||||||||||
| + | |||||||||||||||
| Property / PubMed ID: 14503945 / rank | |||||||||||||||
| + | Normal rank | ||||||||||||||
| Property / Publication Date | |||||||||||||||
| + | 2003
| ||||||||||||||
| Property / Publication Date: 2003 / rank | |||||||||||||||
| + | Normal rank | ||||||||||||||
| Property / Published In Name String | |||||||||||||||
| + | Cancer Biother. Radiopharm. | ||||||||||||||
| Property / Published In Name String: Cancer Biother. Radiopharm. / rank | |||||||||||||||
| + | Normal rank | ||||||||||||||
| Property / Volume | |||||||||||||||
| + | 18 | ||||||||||||||
| Property / Volume: 18 / rank | |||||||||||||||
| + | Normal rank | ||||||||||||||
| Property / title | |||||||||||||||
| + | 131I-anti CD20 radioimmunotherapy of relapsed or refractory non-Hodgkins lymphoma: a phase II clinical trial of a nonmyeloablative dose regimen of chimeric rituximab radiolabeled in a hospital (English) | ||||||||||||||
| Property / title: 131I-anti CD20 radioimmunotherapy of relapsed or refractory non-Hodgkins lymphoma: a phase II clinical trial of a nonmyeloablative dose regimen of chimeric rituximab radiolabeled in a hospital (English) / rank | |||||||||||||||
| + | Normal rank | ||||||||||||||
| Property / Page(s) | |||||||||||||||
| + | 513-524 | ||||||||||||||
| Property / Page(s): 513-524 / rank | |||||||||||||||
| + | Normal rank | ||||||||||||||
| Property / Fourth Author string | |||||||||||||||
| + | Claringbold PG | ||||||||||||||
| Property / Fourth Author string: Claringbold PG / rank | |||||||||||||||
| + | Normal rank | ||||||||||||||
| Property / Fifth Author string | |||||||||||||||
| + | Leahy MF | ||||||||||||||
| Property / Fifth Author string: Leahy MF / rank | |||||||||||||||
| + | Normal rank | ||||||||||||||
Latest revision as of 13:52, 22 May 2020
Cited in: "Targeting cancer stem cell pathways for cancer therapy" in Signal Transduct Target Ther; 2020 ; 5 8
| Language | Label | Description | Also known as |
|---|---|---|---|
| English |
Turner JH, et al. Cancer Biother. Radiopharm. (2003) cited as Ref 550 in DOI: 10.1038/s41392-020-0110-5
|
Cited in: "Targeting cancer stem cell pathways for cancer therapy" in Signal Transduct Target Ther; 2020 ; 5 8
|
Statements
Turner JH
0 references
Martindale AA
0 references
Boucek J
0 references
2003
0 references
Cancer Biother. Radiopharm.
0 references
18
0 references
131I-anti CD20 radioimmunotherapy of relapsed or refractory non-Hodgkins lymphoma: a phase II clinical trial of a nonmyeloablative dose regimen of chimeric rituximab radiolabeled in a hospital (English)
0 references
513-524
0 references
Claringbold PG
0 references
Leahy MF
0 references
